Prospective Grant of an Exclusive Patent License: Manufacturing and Testing of PVSRIPO in the Treatment of Solid, Non-lymphoid Tumors Expressing Poliovirus Receptor CD155, 23014 [2017-10155]
Download as PDF
23014
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated Exclusive Patent
License. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–10154 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Manufacturing and
Testing of PVSRIPO in the Treatment
of Solid, Non-lymphoid Tumors
Expressing Poliovirus Receptor CD155
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to Istari Oncology
Incorporated located in North Carolina,
U.S.A.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before June 5, 2017 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Lauren
Nguyen-Antczak, Ph.D., J.D., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702, Telephone: (240) 276–5530;
Facsimile: (240) 276–5504, Email:
lauren.nguyen-antczak@nih.gov.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
Intellectual Property
United States Provisional Patent
Application No. 62/173,777, filed June
10, 2015 and entitled ‘‘Processes for
Production and Purification of Nucleic
Acid Containing Compositions’’ [HHS
Reference No. E–267–2014/0–US–01];
PCT Patent Application PCT/US2016/
036888, filed E–267–2014/0–PCT–02
and entitled ‘‘Processes for Production
and Purification of Nucleic Acid
Containing Compositions’’ [HHS
Reference No. E–267–2014/0–PCT–02];
United States Provisional Patent
Application No. 62/199,663, filed July
31, 2015 and entitled ‘‘Methods of
Analyzing Virus-Derived Therapeutics’’
[HHS Reference No. E–240–2015/0–US–
01];
PCT Patent Application PCT/US2016/
044788, filed July 29, 2016 and entitled
‘‘Methods of Analyzing Virus-Derived
Therapeutics’’ [HHS Reference No. E–
240–2015/1–PCT–01]; and U.S. and
foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Manufacturing and Testing
of PVSRIPO in the Treatment of Solid,
Non-lymphoid Tumors expressing
Poliovirus Receptor CD155, wherein
PVSRIPO is genetically recombinant,
non-pathogenic poliovirus:rhinovirus
chimera that consists of the genome of
the live attenuated poliovirus serotype 1
(SABIN) vaccine (PV1S) with its cognate
IRES element replaced with that of
HRV2.’’
The E–267–2014 technology discloses
improved methods for large scale
production of highly purified,
therapeutic grade, oncolytic
polioviruses. Invention processes
provide industrial scale, and cGMP
compliant manufacturing of PVSRIPO.
The E–240–2015 technology discloses
improved methods for detecting genetic
micro-heterogeneity in manufactured
batches of RNA virus-derived
therapeutics, such as PVSRIPO.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 12, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–10155 Filed 5–18–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Dianca Finch, 240–669–5503;
dianca.finch@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Products for Treatment and Prevention
of Ebola Zaire Disease
Description of Technology
Scientists at the NIAID Vaccine
Research Center have developed human
E:\FR\FM\19MYN1.SGM
19MYN1
Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Page 23014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10155]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Manufacturing
and Testing of PVSRIPO in the Treatment of Solid, Non-lymphoid Tumors
Expressing Poliovirus Receptor CD155
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Commercialization Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
notice to Istari Oncology Incorporated located in North Carolina,
U.S.A.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before June 5, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Commercialization
Patent License should be directed to: Lauren Nguyen-Antczak, Ph.D.,
J.D., Senior Licensing and Patenting Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD
20892-9702 (for business mail), Rockville, MD 20850-9702, Telephone:
(240) 276-5530; Facsimile: (240) 276-5504, Email: lauren.nguyen-antczak@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 62/173,777, filed
June 10, 2015 and entitled ``Processes for Production and Purification
of Nucleic Acid Containing Compositions'' [HHS Reference No. E-267-
2014/0-US-01];
PCT Patent Application PCT/US2016/036888, filed E-267-2014/0-PCT-02
and entitled ``Processes for Production and Purification of Nucleic
Acid Containing Compositions'' [HHS Reference No. E-267-2014/0-PCT-02];
United States Provisional Patent Application No. 62/199,663, filed
July 31, 2015 and entitled ``Methods of Analyzing Virus-Derived
Therapeutics'' [HHS Reference No. E-240-2015/0-US-01];
PCT Patent Application PCT/US2016/044788, filed July 29, 2016 and
entitled ``Methods of Analyzing Virus-Derived Therapeutics'' [HHS
Reference No. E-240-2015/1-PCT-01]; and U.S. and foreign patent
applications claiming priority to the aforementioned applications.
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Manufacturing and Testing of PVSRIPO in the
Treatment of Solid, Non-lymphoid Tumors expressing Poliovirus Receptor
CD155, wherein PVSRIPO is genetically recombinant, non-pathogenic
poliovirus:rhinovirus chimera that consists of the genome of the live
attenuated poliovirus serotype 1 (SABIN) vaccine (PV1S) with its
cognate IRES element replaced with that of HRV2.''
The E-267-2014 technology discloses improved methods for large
scale production of highly purified, therapeutic grade, oncolytic
polioviruses. Invention processes provide industrial scale, and cGMP
compliant manufacturing of PVSRIPO. The E-240-2015 technology discloses
improved methods for detecting genetic micro-heterogeneity in
manufactured batches of RNA virus-derived therapeutics, such as
PVSRIPO.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Commercialization Patent
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: May 12, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-10155 Filed 5-18-17; 8:45 am]
BILLING CODE 4140-01-P